Show simple item record

dc.contributor.authorLewey, Jenniferen_US
dc.contributor.authorWei, Wenhuien_US
dc.contributor.authorLauffenburger, Julie Cen_US
dc.contributor.authorMakanji, Sagaren_US
dc.contributor.authorChant, Alanen_US
dc.contributor.authorDiGeronimo, Jeffen_US
dc.contributor.authorNanchanatt, Ginaen_US
dc.contributor.authorJan, Sairaen_US
dc.contributor.authorChoudhry, Niteesh Ken_US
dc.date.accessioned2017-12-06T16:22:41Z
dc.date.issued2017en_US
dc.identifier.citationLewey, Jennifer, Wenhui Wei, Julie C Lauffenburger, Sagar Makanji, Alan Chant, Jeff DiGeronimo, Gina Nanchanatt, Saira Jan, and Niteesh K Choudhry. 2017. “Targeted Adherence Intervention to Reach Glycemic Control with Insulin Therapy for patients with Diabetes (TARGIT-Diabetes): rationale and design of a pragmatic randomised clinical trial.” BMJ Open 7 (10): e016551. doi:10.1136/bmjopen-2017-016551. http://dx.doi.org/10.1136/bmjopen-2017-016551.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:34493280
dc.description.abstractIntroduction: Adherence to and persistence of medications for chronic diseases remains poor and many interventions to improve medication use have only been modestly effective. Targeting interventions to patients who are most likely to benefit should improve their efficiency and clinical impact. This study aims to test the impact of three cost-equivalent pharmacist-led interventions on insulin persistence and glycaemic control among patients with diabetes. Methods and analysis TARGIT-Diabetes (Targeted Adherence Intervention to Reach Glycemic Control with Insulin Therapy for patients with Diabetes) is a randomised controlled trial that will evaluate three different multifaceted pharmacist-outreach strategies for improving long-term insulin use among individuals with diabetes. We will randomise 6000 patients in a large insurer to one of three arms. The arms are designed to deliver an increasingly intensive intervention to a progressively targeted population, identified using predictive analytics. The central component of the intervention in all arms is a tailored telephone consultation with a pharmacist which varies across arms based on the: (A) proportion of patients offered the intervention and (B) intervention intensity, including follow-up frequency and cointerventions such as text reminders and interactions with patients’ providers. The primary outcome is insulin persistence, assessed using pharmacy claims data, and the secondary outcomes are glycaemic control as measured by glycosylated haemoglobin values, healthcare utilisation and healthcare spending. Ethics and dissemination This protocol has been approved by the Institutional Review Board of Brigham and Women’s Hospital and the Privacy Board of Horizon Blue Cross Blue Shield of New Jersey. We plan to present the results of this trial at national meetings and in manuscripts submitted to peer-reviewed journals. Trial registration number NCT 02846779.en
dc.language.isoen_USen
dc.publisherBMJ Publishing Groupen
dc.relation.isversionofdoi:10.1136/bmjopen-2017-016551en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665263/pdf/en
dash.licenseLAAen_US
dc.subjectProtocolen
dc.subjectorganisation of health servicesen
dc.subjecttelemedicineen
dc.titleTargeted Adherence Intervention to Reach Glycemic Control with Insulin Therapy for patients with Diabetes (TARGIT-Diabetes): rationale and design of a pragmatic randomised clinical trialen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalBMJ Openen
dash.depositing.authorLauffenburger, Julie Cen_US
dc.date.available2017-12-06T16:22:41Z
dc.identifier.doi10.1136/bmjopen-2017-016551*
dash.contributor.affiliatedLauffenburger, Julie
dash.contributor.affiliatedChoudhry, Niteesh


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record